Tylenol maker Kenvue is reeling after unsupported claims that its popular drug causes autism. Kennedy is unlikely to stop there. (Photo: Andrew Harnik via Getty Images) https://t.co/hAmj6nnpIV https://t.co/K7IXlXmraI ...

Shares of Kenvue sank about 7.5% ahead of a Sept. 22 White House press conference about what?Place your bets in the latest edition of Pointed, Bloomberg’s weekly news quiz for risk-takers ⤵️ https://t.co/6zUooG9AOi ...

Trump’s warnings about the unproven link between Tylenol use during pregnancy to autism in children risks reinvigorating a barrage of litigation over the issue for its maker Kenvue https://t.co/zsy5a6du0J ...

Company Overview - Kenvue, the maker of Tylenol, experienced a significant stock fluctuation, dropping 7.5% on Monday following comments from President Trump, but rebounded by over 6% at the opening of trading on Tuesday [3][8] - Kenvue was spun off from Johnson & Johnson in 2023 to enhance operational efficiency, and it produces various consumer health products including Band-Aids and Listerine [6] Industry Context - President Trump's remarks linked Tylenol to autism, which Kenvue strongly disputed, emphasizing the importance of the drug for pregnant women facing health risks [5][8] - The announcement by Trump was based on existing studies rather than new research, and it coincided with the activities of Health and Human Services Secretary Robert F. Kennedy Jr., a known vaccine skeptic [4][8] Market Reaction - Analysts, including Citi Investment Research's Filippo Falorni, noted a limited risk of new lawsuits but acknowledged potential negative impacts on Tylenol consumption due to the adverse publicity [8] - Despite the controversy, the lack of new scientific evidence is expected to lead to a positive market reaction for Kenvue's stock [8]

Kenvue stock is rebounding. It may be a largely a case of things-could've-been- worse. ...

Industry Impact & Regulatory Response - The Trump administration advised pregnant women against taking acetaminophen (Tylenol) due to potential links to autism, triggering concerns and potential market reactions [1][2] - FDA is initiating a label update for Tylenol and similar products to reflect potential risks of neurological conditions like autism when taken during pregnancy [2] - The FDA's letter to doctors was more cautious, noting that while studies suggest an association between acetaminophen and autism, a causal relationship hasn't been established [3] - Global regulators like the WHO find no new evidence suggesting Tylenol poses a risk during pregnancy, contrasting with the US stance [8] - Medical communities such as the American College of Obstetrics and Gynecology and the Society for Maternal Fetal Medicine are not changing their views on Tylenol use during pregnancy [8][9] Company & Market Reaction - Ken View (likely referring to a company marketing acetaminophen products) is rebounding despite the announcement, suggesting investor resilience [1][11][14] - Ken View has been proactively pushing back against the alleged link between Tylenol and autism, asserting that no scientific evidence supports it [7] - GSK's old drug, Wooin, previously discontinued, may see its generic versions benefit from an updated label indicating potential use for autism symptoms [4] - GSK clarifies it has no plans to bring Wooin back to market, despite label updates potentially benefiting generic versions [4] Autism Treatment & Research - FDA is moving to approve an old GSK drug to treat autism symptoms, though studies are small and benefits may not be widespread [3][5] - The approved drug, currently used for cancer treatment toxicity, has shown promise in helping non-verbal autism patients, but further research is needed [5][6]

Core Viewpoint - The Trump administration has advised pregnant women against taking acetaminophen, the active ingredient in Tylenol, due to potential links to autism, while the FDA is updating product labels to reflect this concern [1][2][3] Group 1: FDA and Drug Approval - The FDA is beginning the process of updating the label for Tylenol and similar products to indicate a possible association between acetaminophen use during pregnancy and increased risk of neurological conditions like autism [2] - The FDA has communicated to doctors that while studies suggest an association between acetaminophen and autism, a causal relationship has not been established, and there are conflicting studies in the scientific literature [3] - The FDA is also moving to approve an older GSK drug for treating autism symptoms, which has shown some promise in non-verbal patients, although the studies are small and not widely beneficial [4][5] Group 2: Industry Response and Market Reaction - Ken View has been actively pushing back against claims linking Tylenol to autism, asserting that no scientific evidence supports this connection [7] - The medical community, including organizations like the American College of Obstetrics and Gynecology and the Society for Maternal Fetal Medicine, continues to support the use of acetaminophen during pregnancy, indicating a lack of consensus on the issue [8][9] - Despite the controversy, Ken View shares have seen a rebound, suggesting investor confidence remains strong amid the political discourse surrounding the drug [11]

ToplineShares of Tylenol-maker Kenvue jumped more than 6% as trading opened Tuesday, a day after President Donald Trump linked the use of the drug’s active ingredient during pregnancy to increased risk for autism, despite lacking scientific evidence. Economists saw "limited" risk to the pharmaceutical firm's stock, despite some expected impact on Tylenol consumption.Getty ImagesKey FactsKenvue shares rose about 6.2% to around $18 as trading opened Tuesday, following an earlier rally in premarket while rebou ...

Group 1 - Kenvue's stock increased by 5.9% after refuting claims that acetaminophen may lead to autism [1] - Boeing's shares rose by 2.7% following an order from Uzbekistan Airways valued at over $8 billion [1] - Firefly Aerospace's stock fell by 10.9% as Q2 losses exceeded expectations and revenue was also below forecasts [1] Group 2 - AutoZone's stock declined by 2.3% due to Q4 performance falling short of expectations [1] - TSMC's stock increased by 3.9%, reaching a new high, with reports indicating a 20% price increase for the third-generation 3nm process compared to the previous generation [1]

ToplineShares of Tylenol-maker Kenvue jumped more than 6% in premarket trading on Tuesday, a day after President Donald Trump linked the use of the drug’s active ingredient during pregnancy to increased risk for autism, despite lacking scientific evidence. Economists saw "limited" risk to the pharmaceutical firm's stock, despite some expected impact on Tylenol consumption.Getty ImagesKey FactsKenvue shares rose about 6.7% to around $18.10in early trading Tuesday, rebounding from a 7.4% drop on Monday as the ...